Rafferty Asset Management, LLC Aldeyra Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.11 - $8.16 $94,515 - $126,227	15,469 Added 6.11%	268,690 $1.79 Million
Q2 2023 Aug 11, 2023	BUY	$7.11 - $11.89 $1.8 Million - $3.01 Million	253,221 New	253,221 $2.12 Million
Q1 2022 May 13, 2022	SELL	$3.25 - $5.17 $692,168 - $1.1 Million	-212,975 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$3.5 - $9.63 $238,532 - $656,303	68,152 Added 47.06%	212,975 $852,000
Q3 2021 Nov 10, 2021	BUY	$7.94 - $11.31 $90,516 - $128,934	11,400 Added 8.54%	144,823 $1.27 Million
Q2 2021 Aug 10, 2021	SELL	$10.44 - $14.85 $307,217 - $436,990	-29,427 Reduced 18.07%	133,423 $1.51 Million
Q1 2021 May 10, 2021	BUY	$6.53 - $14.42 $1.06 Million - $2.35 Million	162,850 New	162,850 $1.94 Million

122

36.3M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $377M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.